Granatin A can act on 30 targets, including TLR4, NOS2, STAT3, MTOR, NFKB1, and PTGS2 in this network, suggesting that it has great potential to improve IBS by inhibiting inflammation. The gene discussed is TLR4; the disease is irritable bowel syndrome.